[HTML][HTML] ALS genetics, mechanisms, and therapeutics: where are we now?
The scientific landscape surrounding amyotrophic lateral sclerosis (ALS) continues to shift
as the number of genes associated with the disease risk and pathogenesis, and the cellular …
as the number of genes associated with the disease risk and pathogenesis, and the cellular …
[HTML][HTML] Improving clinical trial outcomes in amyotrophic lateral sclerosis
Individuals who are diagnosed with amyotrophic lateral sclerosis (ALS) today face the same
historically intransigent problem that has existed since the initial description of the disease in …
historically intransigent problem that has existed since the initial description of the disease in …
Amyotrophic lateral sclerosis: an update for 2018
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motor neurons
and other neuronal cells, leading to severe disability and eventually death from ventilatory …
and other neuronal cells, leading to severe disability and eventually death from ventilatory …
Pharmacotherapy for amyotrophic lateral sclerosis: a review of approved and upcoming agents
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
involving loss of upper and lower motor neurons, with most cases ending in death within 3–5 …
involving loss of upper and lower motor neurons, with most cases ending in death within 3–5 …
[HTML][HTML] Glycogen synthase kinase-3 inhibitors: preclinical and clinical focus on CNS-A decade onward
SM Arciniegas Ruiz, H Eldar-Finkelman - Frontiers in molecular …, 2022 - frontiersin.org
The protein kinase, GSK-3, participates in diverse biological processes and is now
recognized a promising drug discovery target in treating multiple pathological conditions …
recognized a promising drug discovery target in treating multiple pathological conditions …
Hypermetabolism in ALS is associated with greater functional decline and shorter survival
Objective To determine the prevalence of hypermetabolism, relative to body composition, in
amyotrophic lateral sclerosis (ALS) and its relationship with clinical features of disease and …
amyotrophic lateral sclerosis (ALS) and its relationship with clinical features of disease and …
[HTML][HTML] The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration
S Opie-Martin, A Iacoangeli, SD Topp, O Abel… - Nature …, 2022 - nature.com
Superoxide dismutase (SOD1) gene variants may cause amyotrophic lateral sclerosis, some
of which are associated with a distinct phenotype. Most studies assess limited variants or …
of which are associated with a distinct phenotype. Most studies assess limited variants or …
TDP-43 pathology: from noxious assembly to therapeutic removal
Our understanding of amyotrophic lateral sclerosis and frontotemporal dementia has
advanced dramatically since the discovery of cytoplasmic TAR DNA-binding protein 43 (TDP …
advanced dramatically since the discovery of cytoplasmic TAR DNA-binding protein 43 (TDP …
Disease-modifying therapies in amyotrophic lateral sclerosis
A Chiò, L Mazzini, G Mora - Neuropharmacology, 2020 - Elsevier
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of adult life, causing
weakness and wasting of voluntary muscles, associated in about 50% of cases with a …
weakness and wasting of voluntary muscles, associated in about 50% of cases with a …
The impact of age on genetic testing decisions in amyotrophic lateral sclerosis
PR Mehta, A Iacoangeli, S Opie-Martin, JJFA van Vugt… - Brain, 2022 - academic.oup.com
Amyotrophic lateral sclerosis (ALS) is a heterogeneous neurodegenerative syndrome. In up
to 20% of cases, a family history is observed. Although Mendelian disease gene variants are …
to 20% of cases, a family history is observed. Although Mendelian disease gene variants are …